contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Xvivo Perfusion is a medical technology company. The company provides solutions for lung transplantation. Examples of products that the company delivers include needles, organ storage, and cooling solutions. The products are resold to clinics and research institutes around the global market, with the largest business presence in the Nordics and Europe. The company was established via a spin-off from Vitrolife in 2012 and is headquartered in Gothenburg.

Xvivo Perfusion

Invitation to attend XVIVO’s conference call regarding the presentation of the interim report January-September 2024. The presentation will be held in English.Time: Thursday, October 24 at 2...

<div class="mfn-preamble"><p><strong>Invitation to attend XVIVO’s conference call regarding the presentation of the interim report January-September 2024. The presentation will be held in English.</strong></p></div><div class="mfn-body"><p>Time: Thursday, October 24 at 2.00 pm CET / 8.00 am EST</p><p>If you wish to participate via webcast please use the link below.&nbsp;Via the webcast you are able to ask written questions.&nbsp;<a rel="noopener" href="https://ir.financialhearings.com/xvivo-q3-report-2024">https://ir.financialhearings.com/xvivo-q3-report-2024</a></p><p>If you wish to participate via teleconference please register on the link below.&nbsp;After registration you will be provided phone numbers and a conference ID to access the conference. Via the teleconference you can ask questions verbally.<br><a rel="noopener" href="https://conference.financialhearings.com/teleconference/?id=50046879">https://conference.financialhearings.com/teleconference/?id=50046879</a><br>&nbsp;<br>Participants from XVIVO:<br>Christoffer Rosenblad, CEO<br>Kristoffer Nordström, CFO<br>&nbsp;<br>The press release for XVIVO’s interim report January-September 2024 will be released on October 24, 2024 at 7.30 am CET / 1.30 am EST.<br>&nbsp;<br>Before the conference call, slides will be available at the company web page,&nbsp;<a rel="noopener" href="https://www.xvivogroup.com/investors/reports-and-presentations/">https://www.xvivogroup.com/investors/reports-and-presentations/</a></p><p>Oktober 10, 2024<br>Mölndal<br>XVIVO Perfusion AB (publ)</p></div><div class="mfn-footer mfn-fb9cf3b124f9"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p>Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivogroup.com<br>Kristoffer&nbsp;Nordström, CFO, +46 73 519 21 64, e-mail:&nbsp;kristoffer.nordstrom@xvivogroup.com</p></div><div class="mfn-footer mfn-about mfn-da5f5ee9f867"><p><strong class="mfn-heading-1">About Us</strong></p><hr><p>Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/e6d76d85-7c66-4ce5-8840-c756954a9357/conference-call-on-interim-report.pdf" class="mfn-generated mfn-primary">Conference call on Interim Report</a></p></div>

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!